Drugs / RSV MEDI ΔM2-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01459198 | Aug 2011 → Jun 2015 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV MEDI ΔM2-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01459198 ↗ |
| Modality | Vaccine | “Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine” NCT01459198 ↗ |
| Route | Intranasal | “Given intranasally once at a baseline study visit, at a dose of 10\^5 or 10\^6 plaque-forming units (PFU), depending on study arm.” NCT01459198 ↗ |